And I thought I was already awed by oral insulin!

Once Encapsulation Systems' U-Strip™ Insulin Patch hits the market, it will be the first wearable, programmable and non-invasive drug delivery system for diabetics dependent on insulin.

Encapsulation Systems, Inc. - the maker of this novel insulin patch - showcases the U-Strip Insulin System at the American Diabetes Association 67th Annual Scientific Sessions, June 22-26, 2007, McCormick Place Convention Center, Chicago, Il on Booth Number 848.

According to Bruce K. Redding, Jr., President and CEO, Encapsulation Systems, based in Havertown, Pennsylvania:

"The U-Strip Insulin Patch is an ultrasonic drug delivery system using an alternating sonic transmission to effect pore dilation and deposit large molecule drugs into the dermis.

Although our primary market is Type 2 diabetics, our insulin delivery transdermal patch is able to deliver a basal and bolus dose of insulin under a programmable regimen to both Type 1 and Type 2 diabetics."

Currently, the U-Strip™ Insulin Patch is in Phase-2 clinical trials and not yet approved for human use by the FDA.

Find more details from MarketWire.